Advanced Antibody Explorers
“We bring
science to life.”
AAX Biotech is committed to advancing next-generation therapies for a range of diseases. With a focus on antibody-based medicines, our proprietary technologies aim to solve key challenges in drug development. Our vision is to establish AAX as a leading, highly competitive partner serving the bio-pharma industry worldwide.
About us
We are a research-driven company focused on enabling and accelerating the development of highly effective antibody-based medicines. By offering innovative solutions to well-recognized challenges in the rapidly expanding biotherapeutics market, we aim to accelerate drug development and improve therapeutic outcomes.
News
.
News .
-
AAX Biotech is attending BIO 2024
May 16, 2024
AAX Biotech will be represented by CEO Maria Lisa Knudsen at BIO 2024 in San Diego (June 3-6)!
We are looking forward to meeting with current and future pharma partners to discuss drug development, and how our unique technologies Seqitope™ and Opti-mAb™ accelerate drug development and enable the development of next-generation antibody therapeutics that are more efficient and have higher developability.
Please feel free to connect with us if you are attending too!
-
AAX Biotech is attending Nordic Health Summit Japan 2024
April 22, 2024
AAX Biotech will be attending the Nordic Health Summit Japan 2024 (virtually), taking place on April 25, 2024 in Tokyo Japan!
At this partnering conference, we look forward to meeting with Japanese pharma companies to discuss AAX Biotech technologies Seqitope™ and Opti-mAb™ to accelerate drug development and enable the development of next-generation antibody therapeutics that are more efficient and with higher developability.
Please feel free to reach out to our CEO Maria Lisa Knudsen to schedule a meeting.
-
AAX Biotech's Technology to be Utilized in BioArctic’s Research Project
April 17, 2024
Biotech company AAX Biotech, specializing in innovative technologies for improving antibody-based medicines, is excited to announce that BioArctic AB, a renowned Swedish biopharma company focused on neurodegenerative diseases, has decided to utilize AAX Biotech's proprietary epitope mapping technology, Seqitope™.
This marks a significant milestone for AAX Biotech, highlighting the company's role in advancing research with its Seqitope™ technology—a high-resolution, high-throughput method for antibody epitope mapping that accelerates the development of efficacious therapeutics.
